Sesen Bio Inc.

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), at the Company's Special Meeting of Stockholders (the “Special Meeting”) held earlier today. Dr.

Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update. Business Update On February 13, 2023, following extensive engagement with Sesen Bio stockholders, Sesen Bio and Carisma Therapeutics, Inc. (“Carisma”) further amended the previously amended merger agreement announced on December 29, 2022.

Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends that stockholders vote “FOR” all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), in advance of the Company's upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for March 2, 2023.

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that Institutional Shareholder Services (“ISS”) recommends that stockholders vote “FOR” all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), at the Company's upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for March 2, 2023.

Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. (“Carisma”) management team on Tuesday, February 21, 2023, at 8:00 am ET. The discussion will cover Sesen Bio's pending merger with Carisma, as well as Carisma's corporate strategy and clinical programs. Sesen Bio stockholders can submit questions in advance to ir@sesenbio.com.

Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that BML Investment Partners, L.P. (“BML”), one of Sesen Bio's top stockholders, intends to vote all of its shares in support of the Company's pending merger with Carisma Therapeutics Inc. (“Carisma”). BML owned approximately 4.1% of the Company's outstanding common stock as of the close of business on January 17, 2023, the record date for the Special Meeting of Stockholders.

BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

CAMBRIDGE, Mass. & PHILADELPHIA--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the companies have reached a voting and support agreement (the “Support Agreement”) with Bradley L. Radoff and Michael Torok (together with their respective affiliates, the “Investor Group”).

Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sesen Bio, Inc. (NASDAQ: SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. (“Carisma”). The presentation can be found at www.SesenBioandCarisma.com.

Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”) today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company's non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company's common stock is subject to delisting.

Sesen Bio Receives NASDAQ Delisting Notice

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company's confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the “Investor Group”):

Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders

HOUSTON--( BUSINESS WIRE )--Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio”), today issued the following open letter to the Boards of Directors (collectively, the “Boards”) of Sesen Bio and Carisma Therapeutics Inc. (“Carisma” and together with Sesen Bio, the “Companies”):

Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sesen Bio, Inc. (Nasdaq: SESN) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's pending merger with Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies. Sesen Bio will commence mailing the definitive proxy statement / prospectus to its stockholders on or about January 24, 2023.

Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics

HOUSTON--( BUSINESS WIRE )--Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today issued the following open letter to the Company's Board of Directors (the “Board”) regarding the proposed merger with Carisma Therapeutics Inc. (“Carisma”):

Investor Group Issues Letter to Sesen Bio's Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma Merger

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company's confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) as the best path forward for stockholders.

Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics

HOUSTON--( BUSINESS WIRE )--Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today reiterated their intent to vote AGAINST the Company's proposed merger with Carisma Therapeutics Inc. (“Carisma”) through the following statement:

Investor Group Reiterates Intent to Vote AGAINST Sesen Bio's Value-Destructive Merger with Carisma

CAMBRIDGE, Mass. & PHILADELPHIA--( BUSINESS WIRE )--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced an amendment to their previously announced merger agreement dated September 20, 2022.

Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger

NEW YORK , Dec. 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sesen Bio, Inc. ("Sesen" or the "Company") (NASDAQ: SESN), in connection with the proposed merger of the Company with Carisma Therapeutics Inc. ("Carisma"). Under the merger agreement, Carisma shareholders will receive newly issued shares of Sesen common stock pursuant to an exchange ratio formula set forth in the merger agreement.

SHAREHOLDER ALERT: Weiss Law Investigates Sesen Bio, Inc.

SESEN BIO, INC. (SESN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?

Fintel reports that Radoff Bradley Louis has filed a 13D form with the SEC disclosing ownership of 6,000,000 shares of Sesen Bio Inc (SESN).

Bradley Louis Radoff Discloses Activist Position in SESN / Sesen Bio

American Rebel Holdings Inc

Digital Brands Group Inc

Faraday Future Intelligent Electric

New Gold

SmileDirectClub

Tenax Therapeutics

Penny stocks under $1: Are they worth the risk to buy right now? The post 7 Cheap Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Cheap Penny Stocks To Buy For Under $1 Right Now

Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update

In the latest trading session, SESEN BIO, INC. (SESN) closed at $0.50, marking no change from the previous day.

SESEN BIO, INC. (SESN) Flat As Market Gains: What You Should Know

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sesen Bio, Inc. (NASDAQ: SESN) and Carisma Therapeutics Inc. is fair to Sesen Bio shareholders. Pre-merger Sesen Bio shareholders are expected to own approximately 41.7% of the combined company. Halper Sadeh encourages Sesen Bio shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade

SESN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sesen Bio, Inc. Is Fair to Shareholders

CAMBRIDGE, Mass. & PHILADELPHIA--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma's proprietary cell therapy platform that utilizes engineered m

Sesen Bio and Carisma Therapeutics Announce Merger Agreement

After losing some value lately, a hammer chart pattern has been formed for SESEN BIO, INC. (SESN), indicating that the stock has found support.

News for Sesen Bio Inc. Stock (SESN)